Compare
Tectonic Therapeutic, Inc. vs enGene Therapeutics Inc. vs Allogene Therapeutics, Inc. vs Tarsus Pharmaceuticals, Inc.
| Latest fiscal year | Tectonic Therapeutic, Inc. TECX | enGene Therapeutics Inc. ENGN | Allogene Therapeutics, Inc. ALLO | Tarsus Pharmaceuticals, Inc. TARS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-10-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $0 | $451.36M |
| Revenue growth (YoY) | n/a | n/a | -100.0% | +146.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | -15.7% |
| Net margin | n/a | n/a | n/a | -14.7% |
| Net income | -$74.15M | -$117.30M | -$190.89M | -$66.42M |
| EPS (Diluted) | -$4.05 | $2.29 | -$0.87 | -$1.59 |
| Operating cash flow | -$60.08M | -$99.24M | -$149.25M | -$12.45M |
| Free cash flow | -$60.29M | -$100.72M | -$149.63M | -$22.31M |
| Cash & equivalents | $253.80M | $50.15M | $51.69M | $183.64M |
| Total assets | $261.04M | $221.47M | $415.90M | $562.16M |
| Total liabilities | $9.71M | $53.76M | $123.36M | $218.73M |
| Shareholders' equity | $251.33M | $167.71M | $292.54M | $343.43M |
| Return on year-end equity | -29.5% | -69.9% | -65.3% | -19.3% |
| Shares outstanding | 18.74M | 52.02M | 229.41M | 42.55M |
Revenue, most recent five fiscal years
| Fiscal year | Tectonic Therapeutic, Inc. | enGene Therapeutics Inc. | Allogene Therapeutics, Inc. | Tarsus Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | $0 Ended 2025-12-31 | $451.36M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $22.0K Ended 2024-12-31 | $182.95M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $95.0K Ended 2023-12-31 | $17.45M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $156.0K Ended 2022-12-31 | $25.82M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $114.09M Ended 2021-12-31 | $57.03M Ended 2021-12-31 |